Filing Details

Accession Number:
0000950170-24-030485
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-13 06:04:11
Reporting Period:
2024-03-08
Accepted Time:
2024-03-13 06:04:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818794 Dyne Therapeutics Inc. DYN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1691005 Gatti Susanna High 1560 Trapelo Road
Waltham MA 02451
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-03-08 26,908 $26.66 159,383 No 4 S Direct
Common Stock Disposition 2024-03-08 291 $27.41 159,092 No 4 S Direct
Common Stock Disposition 2024-03-11 2,292 $25.70 156,800 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.32 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.39 to $27.42, inclusive.
  3. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive.
  5. Includes 145,829 unvested RSUs.